Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170882 · ClinicalTrials.gov registry record · Phase 2
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT03170882 is a Phase 2 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT03170882, a Phase 2 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be compared to another medicine called pomalidomide, given with dexamethasone with people with the same condition. Relapsed means the previous cancer treatment stopped working, over time. Refractory means they did not respond to previous cancer treatment. Another aim is to check for side effects from the study medicines. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance. * Ixazomib capsules, given with dexamethasone tablets * Pomalidomide capsules, given with dexamethasone tablets All participants will take their study medicine on specific days during a 28-day cycle. The 1st dose of study medicines in each 28-day cycle will take place in the clinic, The other doses of the study medicines will be taken at home. This will happen for 6 cycles. After this, all study medicines will be taken at home. After treatment, participants will visit the clinic every 12 weeks for a check-up. If participants cannot attend their clinic for an important reason (for example, due to the COVID-19 pandemic), the clinic will make alternative arrangements using their local procedures.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2021-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170882
The ClinicalTrials.gov registry entry for NCT03170882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03170882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170882 about?
NCT03170882 is a clinical study titled "A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma". The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma. It will be compared to another medicine called pomalidomide, given with dexamethasone with people with the same condition. Relapse...
What is the current status of trial NCT03170882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2017-08-01. Estimated completion is 2021-11-26.
What interventions are being tested in trial NCT03170882?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03170882?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.